Religiosity in patients with amyotrophic lateral sclerosis, a cross-country comparison
-
Published:2023-03-16
Issue:8
Volume:32
Page:2235-2246
-
ISSN:0962-9343
-
Container-title:Quality of Life Research
-
language:en
-
Short-container-title:Qual Life Res
Author:
Ciećwierska Katarzyna, Lulé Dorothée, Helczyk Olga, Nieporęcki Krzysztof, Bielecki Maksymilian, Baader Susanne, Ludolph Albert C., Kuźma-Kozakiewicz MagdalenaORCID
Abstract
Abstract
Purpose
Amyotrophic lateral sclerosis (ALS) is a progressive motor impairment leading to early death. Religiousness is one of the factors potentially alleviating the psychological burden of patients. However, its role might vary according to cultural context. Our study aimed to analyze religiosity, and its clinical, psychological and socio-demographic correlates in ALS patients and controls, comparing two European countries with different cultural backgrounds.
Methods
268 Polish and German ALS patients, including 18 with locked-in syndrome (LIS) and 198 healthy controls (HC) were interviewed about religiousness, quality of life (Qol), depression, functional status and pain. A follow-up was conducted on 71 patients.
Results
Polish subjects had a significantly higher level of public, private and general religiosity than the German sample. Importantly, we found no difference in total and public religiousness between ALS patients and HC within either population. Only the private religiousness was significantly higher in German patients compared to controls. In the same sample, private religiousness correlated with functional impairment due to disease progression. In ALS groups and LIS patients, religiousness did not correlate with any disease-associated factors: disease duration, pain, Qol or depression. Follow-up comparisons in the ALS group revealed worsening functional status, increased depression and no significant change in religiosity.
Conclusions
Religiosity was linked to the cultural background rather than ALS. Generally, it did not correlate with clinical, psychological and socio-demographic parameters and was stable throughout disease progression. The only exception was the relationship between the functional decline and private religiosity among German patients.
Funder
EU Joint Programme – Neurodegenerative Disease Research ERA-NET-E-Rare Bundesministerium für Bildung und Forschung
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference47 articles.
1. Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011). Amyotrophic lateral sclerosis. The Lancet, 377(9769), 942–955. https://doi.org/10.1016/S0140-6736(10)61156-7 2. Andersen, P. M., Abrahams, S., Borasio, G. D., Carvalho, M., Chio, A., Van Damme, P., Hardiman, O., Kollewe, K., Morrison, K. E., Petri, S., Pradat, P. F., Silani, V., Tomik, B., Wasner, M., & Weber, M. (2012). EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. European Journal of Neurology, 19(3), 360–375. https://doi.org/10.1111/j.1468-1331.2011.03501.x 3. Goldstein, L. H., & Abrahams, S. (2013). Changes in cognition and behaviour in amyotrophic lateral sclerosis: Nature of impairment and implications for assessment. The Lancet Neurology, 12, 368–380. https://doi.org/10.1016/S1474-4422(13)70026-7 4. Lulé, D., Zickler, C., Häcker, S., Bruno, M. A., Demertzi, A., Pellas, F., Laureys, S., & Kübler, A. (2009). Life can be worth living in locked-in syndrome. Progress in Brain Research, 177, 339–351. https://doi.org/10.1016/S0079-6123(09)17723-3 5. Yoshino, H. (2019). Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 19(3), 185–193. https://doi.org/10.1080/14737175.2019.1581610
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|